Ken Fisher Loves These 5 Defensive Stocks

Page 1 of 5

In this article, we discuss 5 defensive stocks that Ken Fisher loves. If you want to read our detailed analysis of Fisher’s investment philosophy, hedge fund returns, and history, go directly to Ken Fisher Loves These 10 Defensive Stocks.

5. Eli Lilly and Company (NYSE:LLY)

Fisher Asset Management’s Stake Value: $2.15 billion

Percentage of Fisher Asset Management’s Portfolio: 1.26%

Number of Hedge Fund Holders: 53

Eli Lilly and Company (NYSE:LLY) is an Indiana-based pharmaceutical company. One of the company’s most significant achievements to date is being the first company to mass-produce the polio vaccine. As of May 13, Eli Lilly and Company (NYSE:LLY) has a dividend yield of 1.34% with an annual payout of $3.92. 

After three consecutive EPS misses, Eli Lilly and Company (NYSE:LLY) outperformed the estimates by 13.72% in the first quarter of 2022. The forecast was at $2.30, while the company posted an EPS of $2.62. On the revenue side, the company had no problem surpassing the analyst estimates of $7.35 billion by $457.21 million. Eli Lilly and Company (NYSE:LLY) reported a revenue of $7.81 billion.

On June 6, Mizuho analyst Vamil Divan maintained a Buy rating on Eli Lilly and Company (NYSE:LLY)’s shares with a price target of $356. The analyst was impressed by the results from the SURMOUNT-1 trial for Mounjaro at American Diabetes Association Annual Meeting. The analyst believes that the diabetes drug Mounjaro’s sales will surpass $14 billion by 2030.

Saturna Capital mentioned Eli Lilly and Company (NYSE:LLY) in its fourth-quarter 2021 investor letter. Here is what the fund said:

“Industrials and pharmaceutical companies were among the Amana Income Fund’s strongest performers in the fourth quarter. Industrials and pharmaceutical companies were among the Amana Income Fund’s strongest performers in the fourth quarter. Drug maker Eli Lilly is represented in the 10 Largest Contributors.”

Page 1 of 5